OTOGL

Across TCGA pan-cancer cohorts, OTOGL Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated OTOGL data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher OTOGL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OTOGL expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

PAAD, UCEC, and OV are the cancer types where OTOGL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.028	0.614	<.001	24	view →
UCEC	DFS	Median	All	0.935	0.614	.001	20	view →
OV	DFS	Median	All	0.120	0.542	<.001	18	view →
BRCA	DFS	Median	III,IV	0.547	0.880	<.001	12	view →
LUAD	OS	Median	III,IV	0.210	0.710	<.001	9	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LIHC	DFS	Median	All	0.104	0.530	.007	3	view →
STAD	DFS	Median	III,IV	0.842	0.333	.043	2	view →
SKCM	DFS	Median	II,III,IV	0.707	0.525	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

OTOGL–PAAD (OS)

Open the PAAD breakdown →